Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.38 |
| ▸ | FNTB | P49356 | 3/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707093 | 0.91 | ENPP2 (0.39) | ENPP2 | |
| SCHEMBL4568507 | 0.91 | MTNR1A (0.41) | KDM4EFNTAFNTBMTNR1AMTNR1B | |
| SCHEMBL3704841 | 0.90 | FNTA (0.38) | FNTAFNTBMTNR1AMTNR1B | |
| SCHEMBL3709676 | 0.89 | KDM4E (0.43) | KDM4ELMNAHTTENPP2FNTA | |
| SCHEMBL4568573 | 0.86 | ENPP2 (0.42) | KDM4ELMNAHTTENPP2MTNR1A | |
| SCHEMBL4568588 | 0.86 | KDM4E (0.41) | KDM4ELMNAHTTENPP2FNTA | |
| SCHEMBL3706080 | 0.85 | TLR9 (0.42) | ENPP2FNTAFNTBMTNR1AMTNR1B | |
| SCHEMBL3708768 | 0.85 | TUBB4A (0.38) | ENPP2 | |
| SCHEMBL3713247 | 0.84 | MTNR1A (0.44) | KDM4ELMNAHTTMTNR1AMTNR1B | |
| SCHEMBL4568572 | 0.84 | KDM4E (0.41) | KDM4ELMNAHTTENPP2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151292-A | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL | 2014-11-19 | — | — | CN | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2474530-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-102498097-A | Indole derivatives or pharmaceutically acceptable salts thereof | KISSEI PHARMACEUTICAL | 2012-06-13 | — | — | CN | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | KDM4E 3521/4885LMNA 4472/4885HTT 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.